tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: CTI BioPharma (CTIC) and Atara Biotherapeutics (ATRA)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CTI BioPharma (CTICResearch Report) and Atara Biotherapeutics (ATRAResearch Report) with bullish sentiments.

CTI BioPharma (CTIC)

Needham analyst Gil Blum maintained a Buy rating on CTI BioPharma today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.99.

According to TipRanks.com, Blum ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -25.8% and a 6.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals.

Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $5.55, implying a 155.3% upside from current levels. In a report issued on December 1, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.

See today’s best-performing stocks on TipRanks >>

Atara Biotherapeutics (ATRA)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics today and set a price target of $41.00. The company’s shares closed last Wednesday at $15.32.

According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.9% and a 43.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Coherus Biosciences, and Unity Biotechnology.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $33.00 average price target, representing an 110.7% upside. In a report issued on December 7, William Blair also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed